These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 30472749)

  • 21. Calcipotriol/betamethasone dipropionate aerosol foam in the treatment of psoriasis: new perspectives for the use of an innovative topical treatment from real-life experience.
    Fabbrocini G; Dauden E; Jalili A; Bewley A
    G Ital Dermatol Venereol; 2020 Apr; 155(2):212-219. PubMed ID: 32394674
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Matching-adjusted indirect comparison of efficacy outcomes in trials of calcipotriol plus betamethasone dipropionate foam and cream formulations for the treatment of plaque psoriasis.
    Papp KA; Thoning H; Gerdes S; Megna M; Brandi H; Jablonski Bernasconi MY; Yélamos O
    J Dermatolog Treat; 2022 Nov; 33(7):3005-3013. PubMed ID: 35875991
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness of calcipotriol/betamethasone dipropionate aerosol foam in patients with small versus large plaque psoriasis in routine practice in South Korea.
    Jo SJ; Park CJ; Bang CH; Jeong KH; Shin BS; Kim DH; Song HJ; Lee JH; Kim Y; Choi S; Youn SW
    J Dermatol; 2024 Jul; 51(7):1010-1016. PubMed ID: 38716641
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Prospective, Open-Label Study Evaluating Adjunctive Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam in Psoriasis Patients With Inadequate Response to Biologic Therapy.
    Bagel J; Zapata J; Nelson E
    J Drugs Dermatol; 2018 Aug; 17(8):845-850. PubMed ID: 30124723
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treating Scalp Psoriasis with Calcipotriene/Betamethasone Dipropionate Fixed-dose Combination Cutaneous Foam: Review of Phase 2 Data.
    Petersen B; Lebwohl M
    J Drugs Dermatol; 2020 Aug; 19(8):784-786. PubMed ID: 32820879
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhanced vasoconstrictor potency of the fixed combination calcipotriol plus betamethasone dipropionate in an innovative aerosol foam formulation vs. other corticosteroid psoriasis treatments.
    Queille-Roussel C; Bang B; Clonier F; Lacour JP
    J Eur Acad Dermatol Venereol; 2016 Nov; 30(11):1951-1956. PubMed ID: 27306589
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Itch relief in patients with psoriasis: effectiveness of calcipotriol plus betamethasone dipropionate foam.
    Jalili A; Lebwohl M; Stein Gold L; Andersen SB; Jensen KL; Pink AE; Segaert S; Berg P; Calzavara-Pinton PG; de la Cueva Dobao P; Thaçi D
    J Eur Acad Dermatol Venereol; 2019 Apr; 33(4):709-717. PubMed ID: 30520168
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Maintenance Effect of Calcipotriene 0.05% and Betamethasone Dipropionate 0.064% (Cal/BD) Aerosol Foam in Combination With Apremilast.
    Ozyurekoglu E; Kircik L
    J Drugs Dermatol; 2022 Apr; 21(4):381-386. PubMed ID: 35389594
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Calcipotriol/betamethasone dipropionate formulations for psoriasis: an overview of the options and efficacy data.
    Megna M; Cinelli E; Camela E; Fabbrocini G
    Expert Rev Clin Immunol; 2020 Jun; 16(6):599-620. PubMed ID: 32476507
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PGAxBSA composite versus PASI: Comparison across disease severities and as therapeutic response measure for Cal/BD foam in plaque psoriasis.
    Gold LS; Hansen JB; Patel D; Veverka KA; Strober B
    J Am Acad Dermatol; 2020 Jul; 83(1):131-138. PubMed ID: 32430142
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fixed-Combination Calcipotriene Plus Betamethasone Dipropionate Aerosol Foam Is Well Tolerated in Patients with Psoriasis Vulgaris: Pooled Data from Three Randomized Controlled Studies.
    Menter A; Gold LS; Koo J; Villumsen J; Rosén M; Lebwohl M
    Skinmed; 2017; 15(2):119-124. PubMed ID: 28528605
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Apremilast with Add-On Calcipotriene/Betamethasone Dipropionate for Treating Moderate to Severe Plaque Psoriasis.
    Bagel J; Nelson E; Riley C; Hetzel A
    J Drugs Dermatol; 2020 Dec; 19(12):1149-1155. PubMed ID: 33346509
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Calcipotriol/betamethasone dipropionate aerosol foam for the treatment of psoriasis vulgaris: a review of real-world evidence (RWE).
    Gerdes S; Velasco M; Wu JJ; Hubo M; Veverka KA
    J Dermatolog Treat; 2021 Dec; 32(8):883-893. PubMed ID: 31986945
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real-world experience of calcipotriene and betamethasone dipropionate foam 0.005%/0.064% in the treatment of adults with psoriasis in the United States.
    Wu JJ; Veverka KA; Lu M; Armstrong AW
    J Dermatolog Treat; 2019 Aug; 30(5):454-460. PubMed ID: 30307343
    [No Abstract]   [Full Text] [Related]  

  • 35. Prospective, Observational, Non-Interventional, Multicentre Study on the Efficacy and Tolerability of a New Calcipotriol/Betamethasone Aerosol Foam (Enstilar®) in Patients with Plaque Psoriasis under Daily Practice Conditions.
    Gerdes S; Krakor M; Anger T; Hutt HJ; Körber A
    Dermatology; 2017; 233(6):425-434. PubMed ID: 29502110
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pooled safety analysis of calcipotriol plus betamethasone dipropionate gel for the treatment of psoriasis on the body and scalp.
    Kragballe K; van de Kerkhof P
    J Eur Acad Dermatol Venereol; 2014 May; 28 Suppl 2():10-21. PubMed ID: 24684739
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sub-population analysis of patients with plaque psoriasis treated with calcipotriol/betamethasone aerosol foam; effectiveness and patient satisfaction, according to baseline disease severity and prior psoriasis treatment experience, in a Greek population.
    Rigopoulos D; Lazaridou E; Papadavid E; Georgiou S; Chasapi V; Sfaelos K; Cheliotis G; Ioannides D
    Dermatol Ther; 2022 Jun; 35(6):e15484. PubMed ID: 35373423
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel vehicle for the treatment of psoriasis.
    Dattola A; Silvestri M; Bennardo L; Passante M; Rizzuto F; Dastoli S; Patruno C; Bianchi L; Nisticò SP
    Dermatol Ther; 2020 Jan; 33(1):e13185. PubMed ID: 31830367
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Calcipotriol/betamethasone aerosol foam (Enstilum) for the topical treatment of psoriasis vulgaris in routine practice in Korea: A prospective, noninterventional, multicenter study of treatment outcomes and patient satisfaction.
    Jo SJ; Park CJ; Bang CH; Jeong KH; Shin BS; Kim DH; Park HJ; Kim BS; Song HJ; Lee JH; Youn SW
    J Dermatol; 2022 Nov; 49(11):1085-1095. PubMed ID: 35848089
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of proactive treatment with twice-weekly topical Cal/BD foam in patients with plaque psoriasis undergoing HPA-axis testing: a PSO-LONG subgroup analysis.
    Papp K; Adamski Z; Guenther L; Liljedahl M; Miasik-Pogodzinska A; Szponar-Bojda A; Lynde C; Nutt T; Mørch MH; Tyring S; Werschler W; Reich A; Sadick N; Turchin I; Lacour JP
    J Dermatolog Treat; 2022 Jun; 33(4):2297-2304. PubMed ID: 34365872
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.